A single-center, assessor-blinded, randomized controlled clinical trial to test the safety and efficacy of a novel brain-computer interface controlled functional electrical stimulation (BCI-FES) intervention for gait rehabilitation in the chronic stroke population

Piyashi Biswas,Lucy Dodakian,Po T. Wang,Christopher A. Johnson,Jill See,Vicky Chan,Cathy Chou,Wendy Lazouras,Alison L. McKenzie,David J. Reinkensmeyer,Danh V. Nguyen,Steven C. Cramer,An H. Do,Zoran Nenadic
DOI: https://doi.org/10.1186/s12883-024-03710-3
2024-06-14
BMC Neurology
Abstract:In the United States, there are over seven million stroke survivors, with many facing gait impairments due to foot drop. This restricts their community ambulation and hinders functional independence, leading to several long-term health complications. Despite the best available physical therapy, gait function is incompletely recovered, and this occurs mainly during the acute phase post-stroke. Therapeutic options are limited currently. Novel therapies based on neurobiological principles have the potential to lead to long-term functional improvements. The Brain-Computer Interface (BCI) controlled Functional Electrical Stimulation (FES) system is one such strategy. It is based on Hebbian principles and has shown promise in early feasibility studies. The current study describes the BCI-FES clinical trial, which examines the safety and efficacy of this system, compared to conventional physical therapy (PT), to improve gait velocity for those with chronic gait impairment post-stroke. The trial also aims to find other secondary factors that may impact or accompany these improvements and establish the potential of Hebbian-based rehabilitation therapies.
clinical neurology
What problem does this paper attempt to address?